Connor, Clark & Lunn Investment Management (CC&L)’s Acadia Pharmaceuticals ACAD Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13.9M | Buy |
642,448
+70,187
| +12% | +$1.51M | 0.05% | 318 |
|
|
2025
Q1 | $9.51M | Sell |
572,261
-113,455
| -17% | -$1.88M | 0.04% | 327 |
|
|
2024
Q4 | $12.6M | Sell |
685,716
-286,949
| -30% | -$5.27M | 0.06% | 268 |
|
|
2024
Q3 | $15M | Sell |
972,665
-280,877
| -22% | -$4.32M | 0.07% | 207 |
|
|
2024
Q2 | $20.4M | Buy |
1,253,542
+397,243
| +46% | +$6.46M | 0.09% | 185 |
|
|
2024
Q1 | $15.8M | Buy |
856,299
+228,915
| +36% | +$4.23M | 0.07% | 227 |
|
|
2023
Q4 | $19.6M | Sell |
627,384
-6,085
| -1% | -$191K | 0.09% | 181 |
|
|
2023
Q3 | $13.2M | Buy |
633,469
+97,888
| +18% | +$2.04M | 0.07% | 217 |
|
|
2023
Q2 | $12.8M | Buy |
535,581
+37,403
| +8% | +$896K | 0.06% | 220 |
|
|
2023
Q1 | $9.38M | Buy |
498,178
+8,632
| +2% | +$162K | 0.05% | 264 |
|
|
2022
Q4 | $7.79M | Sell |
489,546
-20,375
| -4% | -$324K | 0.04% | 270 |
|
|
2022
Q3 | $8.34M | Buy |
509,921
+358,405
| +237% | +$5.86M | 0.05% | 231 |
|
|
2022
Q2 | $2.14M | Buy |
151,516
+93,881
| +163% | +$1.32M | 0.01% | 455 |
|
|
2022
Q1 | $1.4M | Buy |
+57,635
| New | +$1.4M | 0.01% | 593 |
|
|
2018
Q3 | – | Sell |
-112,325
| Closed | -$1.72M | – | 906 |
|
|
2018
Q2 | $1.72M | Buy |
+112,325
| New | +$1.72M | 0.01% | 508 |
|
|
2015
Q1 | – | Sell |
-10,400
| Closed | -$330K | – | 559 |
|
|
2014
Q4 | $330K | Buy |
+10,400
| New | +$330K | ﹤0.01% | 446 |
|
|
2013
Q3 | – | Sell |
-13,500
| Closed | -$258K | – | 514 |
|
|
2013
Q2 | $258K | Buy |
+13,500
| New | +$258K | ﹤0.01% | 445 |
|